Objective
The aging population is driving the demand for health care services to an all-time high. This places pressure to find novel measures of producing health services more efficiently and at a lower cost.
In the sphere of hospital pharmacies, antimicrobials are a leading group of medications. The number of doses administered in EU-based hospitals alone is 330 million. In hospital use antibiotics often need to be administered through intravenous (IV) infusion. The manual compounding of IV antibiotics is very time consuming, especially if conducted in the recommended aseptic conditions. Manual compounding is, however, often conducted in non-aseptic conditions, which exposes the IV medicines to microbial contamination. Contaminated medicines are a serious risk to patients.
Hospitals have already begun to adopt automation in care provision. The currently available compounding robots are not, however, capable of rapidly producing large quantities of IV medicines. The demand levels clearly exceed their capacities.
Newico is a pharmacy and laboratory automation company with a sound client base. With the support of the IVANCA project (IntraVenous ANtibiotic Compounding Automation), the goal of Newico is to commercialize a novel, stand-alone IV antibiotic compounding system. The I.V.ICON boasts a capacity level equivalent to 5,5 ward staff. As the I.V.ICON operates in an aseptic environment the produced IV medicines have a significantly longer shelf life (up to 30 times) and their risk of microbial contamination is in the proximity of zero %. Over ten years of use, the I.V.ICON is expected to bring 2,4 Meur savings to the hospital as compared to manual ward based compounding.
The IVANCA project feasibility study is needed to conduct a more detailed market study, learn from an ongoing hospital pilot, make draft plans on arranging manufacturing, elaborate on user needs, conduct an IPR and regulation study in main target markets and make a more detailed business plan.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- engineering and technology electrical engineering, electronic engineering, information engineering electronic engineering control systems
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences medical biotechnology nanomedicine
- medical and health sciences health sciences health care services
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
70600 KUOPIO
Finland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.